Drug intelligence / Profile preview

AD-235

Development stage: Preclinical
Lead developer: Addpharma
Modality: Small Molecules
Administration: Oral

Overview

AD-235 is an incrementally modified drug (IMD) candidate under development by Addpharma, a subsidiary of Yuhan Corporation, for the treatment of hyperlipidemia and hypertension. It is currently in the formulation research stage in South Korea. As a fixed-dose combination (FDC) therapy, AD-235 is designed to improve patient compliance and therapeutic efficacy by combining antihypertensive and lipid-lowering agents into a single oral formulation.

Beyond the preview

Go deeper on AD-235.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD-235.

Explore the full profile